Evogene Ltd. (EVGN) Stock Score, Valuation & Financial Research
Evogene Ltd. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 24/100.
Quick answer for EVGN
Evogene Ltd. currently has a Wall Street Score of 24/100. The stored market price is $0.48. Its financial score is 16/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Evogene Ltd. does
Evogene Ltd., along with its subsidiaries, operates as a computational biology firm. Its core activity involves the discovery and advancement of products across diverse life-science sectors, such as human health and agriculture, primarily leveraging its proprietary Computational Predictive Biology (CPB) platform. This platform, built on deep biological insights, big data analytics, and artificial intelligence, is engineered to digitally identify and strategically guide the creation of life-science solutions derived from microbes, small molecules, and genetic components. The company's operations are structured into three primary divisions: Agriculture, Human Health, and Industrial Applications. Within the Agriculture division, Evogene works on seed traits, agricultural chemicals, and biological products aimed at improving plant yields, with efforts spanning critical crops like corn, soybe
EVGN financial snapshot
- Wall Street Score:
- 24/100
- Current price:
- $0.48
- Market capitalization:
- $4.1M
- Revenue:
- $1.3M
- Net income:
- $-9.1M
- Free cash flow:
- $-13.6M
- Cash:
- $9.4M
- Total debt:
- $2.1M
- EPS:
- -0.91
- Financial score:
- 16/100
- Valuation score:
- 0/100
- Revenue score:
- 14/100
What stands out
- Reported year-over-year revenue growth is -0.7%.
- Free cash flow is $-13.6M, showing cash burn in the current stored period.
- The balance sheet shows $9.4M of cash versus $2.1M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 16/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-07.
How to research EVGN
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.